Leprosy remains a major neglected tropical disease, and its most severe presentations are marked by a paradox: patients with disseminated infection carry high titers of antibodies against Mycobacterium leprae, yet those antibodies do not appear to control the bacterium. A study in iScience asks why, and points the answer at the sugar decorations on the antibody itself. The work shows that the Fc domain of anti-PGL-I IgG1, the dominant subclass, carries a distinctive glycosylation signature, elevated fucosylation together with reduced sialylation and galactosylation, that is ordinarily associated with weakened immune-effector activity. For glycosylation labs, this finding illustrates a familiar point: serum N-glycomics can reveal mechanisms that conventional serology cannot, as Serum N-Glycomics continues to demonstrate across diseases.

Introduction

Phenolic glycolipid-I, or PGL-I, is a major cell-wall component of M. leprae and the basis of widely used leprosy diagnostics. Antibodies against PGL-I track bacterial load, so their presence has long been read as a marker of exposure rather than protection. What the field had not examined is how those antibodies are glycosylated, and whether glycosylation explains their apparent inefficacy in disseminated disease. The new study fills that gap by profiling both total IgG and PGL-I-specific IgG from patient cohorts in the Netherlands and Brazil.

The choice of cohorts matters. The two cohorts—one Dutch, one Brazilian—make it unlikely that the glycoprofile is an artifact of a single population's genetic or environmental background, and the authors report the same Fc glycoprofile in both, strengthening the case that it is a genuine feature of the anti-PGL-I response.

How Fc Glycosylation Shapes Effector Function

The fragment crystallizable region of an antibody does more than anchor the molecule; its N-glycans modulate how the antibody engages immune cells. Low fucosylation boosts natural-killer-cell-mediated antibody-dependent cellular cytotoxicity by strengthening binding to FcγRIIIa and FcγRIIIb, an effect amplified when galactosylation is also high. Conversely, high galactosylation and sialylation promote C1q binding and complement deposition. The anti-PGL-I IgG1 profile reported here runs in the opposite direction—more fucose, less sialic acid, less galactose—a combination consistently linked to dampened effector responses.

Resolving the N-glycans on antigen-specific Fc glycopeptides turns that suspicion into a structural explanation tied to defined glycan features. The same logic underpins therapeutic antibody optimization, where afucosylation is deliberately engineered to sharpen cytotoxicity, and the same Glycan Profiling methods apply directly to pathogen-specific antibodies.

What the Data Show

Across 831 screened patients, anti-PGL-I antibodies were detected in about a third, with IgM more common than IgG overall. Among those with anti-PGL-I IgG, the IgG1 subclass dominated. Glycoprofiling of that IgG1 revealed the skewed Fc glycans: fucosylation high, bisection elevated, and sialylation and galactosylation low. In addition, leprosy patients showed significantly lower galactosylation of their total IgG1 compared with healthy controls in both cohorts—a broader glycosylation change that accompanies, but is distinct from, the antigen-specific signature.

The study's Glycoproteomics workflow applied the GLYcoLISA approach: total IgG was enriched with protein G, PGL-I-specific IgG was affinity-captured on PGL-I-coated plates, and the recovered antibodies were digested with trypsin so that their Fc glycopeptides could be assigned and quantified by nano-LC-MS. This strategy is now standard for antibody characterization because bulk enzymatic release alone can obscure which glycans sit on which subclass. Here it let the authors separate the PGL-I-specific signal from background total IgG, a distinction that matters for any diagnostic or therapeutic interpretation.

Fig. 1 Fc N-glycan profiling workflow for total and PGL-I-specific IgG1. (van Hooij, et al., 2026)

Implications for Diagnostics and Vaccines

If glycosylation blunts the anti-PGL-I response, titer alone may overstate the protective value of those antibodies in disseminated patients. A glycosylation-aware readout could separate patients whose antibodies are functionally armed from those whose are not, potentially sharpening risk stratification. The finding also reframes PGL-I as more than a diagnostic antigen: its specific antibodies may themselves be a readout of a failing effector program, a clue for vaccine design that aims to elicit not just any IgG but effectors with glycosylation suited to Fcγ receptor engagement and complement activation.

The work sits within a wider recognition that infectious-disease antibodies are glycosylation-dependent. Tuberculosis, viral infections, and now leprosy all show glycan skewing that tracks with disease state. N-Glycan Profiling of pathogen-specific antibodies is therefore emerging as a cross-cutting tool for understanding why some hosts control infection and others do not.

Translational Opportunities

The most direct application is biomarker development. A defined Fc glycoprofile on anti-PGL-I IgG could serve as a companion indicator alongside standard PGL-I serology, helping clinics identify patients at risk of progression to disseminated, nerve-damaging disease. Because sialylation and galactosylation are quantifiable on individual glycans, the signature is amenable to targeted mass-spectrometry assays suitable for cohort scaling.

From a measurement standpoint, the study illustrates why Sialic Acid Analysis belongs in the infectious-disease toolkit. Sialylation is a sensitive, information-rich modification whose loss here correlates with impaired complement engagement. Capturing it requires linkage-specific methods, the same methods used to qualify therapeutic antibodies and cancer vaccines, and the same methods that translate a research observation into a clinically reportable metric.

There is also a feedback loop to therapeutic antibodies. Lessons learned from naturally occurring Fc glycans in leprosy, for instance which patterns track with helplessness against a pathogen, inform how we engineer the opposite patterns into monoclonal drugs. In that sense, studying why these antibodies fail teaches us the same rules we exploit when engineering them to succeed.

Toward Glycosylation-Aware Infectious Disease Monitoring

The leprosy finding, from the van Hooij team at LUMC and Fiocruz, is a clear example of a well-established principle in glycobiology—one that CD BioGlyco also applies across diseases in its service work: the sugar coat of a protein often carries the functionally decisive information. Glyco-Biomarker Detection built on site-specific glycoproteomics can surface these signals early, before clinical deterioration is obvious. For neglected diseases with few approved therapies, such readouts may be among the few levers available to improve outcomes.

Longitudinal sampling already shows that the anti-PGL-I Fc signature remains stable after one year of treatment, so the open questions are different: whether that stability reflects biological irreversibility or incomplete treatment response, whether the signature predicts nerve damage, and whether it generalizes to other mycobacterial infections. If it does prove clinically informative, Fc glycosylation profiling could become a routine companion to serology, turning a long-standing paradox of leprosy immunology into a marker clinics could act on.

The study also raises a practical question for serology labs: should routine leprosy monitoring add a glycosylation readout to the standard PGL-I test? The Fc signature is quantitative and, because it sits on a defined IgG1 population, amenable to targeted mass spectrometry that scales to cohorts. The same principle extends beyond leprosy to other mycobacterial and parasitic infections, where host antibody glycosylation increasingly serves as a correlate of protection or failure. For CD BioGlyco, the translational takeaway is that infectious-disease glycosylation is no longer a research curiosity but a measurable clinical variable: pick a well-characterized antigen, profile the Fc glycans of the antibodies raised against it, and ask whether the sugar coat explains why some hosts control infection and others do not.

Related Services & Products

• Glycan Release Service
• Glycan Separation and Purification Service
• Glycan Derivation Service
• Glycomic Quantitation
• Glycoprotein Enrichment
• Glycoprotein Quantification
• Glycoprotein Structure Analysis
• Custom Glycosylation Service
• Flow Cytometry Profiling

Reference

1. van Hooij, A., et al. (2026). Glycosylation profile of Mycobacterium leprae-specific antibodies associated with disseminated infection. iScience. DOI: 10.1016/j.isci.2026.116373.